The discovery and subsequent introduction of dantrolene in 1979 was a major breakthrough in the treatment of malignant hyperthermia (MH) that is responsible for saving hundreds, if not thousands, of lives. However, one of the major challenges in the successful treatment of MH is the need for rapid mixing, suspension, and administration of dantrolene during a crisis.
Eagle Pharmaceuticals, Inc. today announced the U. S. Food and Drug Administration (FDA) has approved Ryanodex® (dantrolene sodium) for injectable suspension indicated for the treatment of malignant hyperthermia (MH), along with the appropriate supportive measures. MH is an inherited and potentially fatal disorder triggered by certain anesthesia agents in genetically susceptible individuals. FDA had designated Ryanodex as an Orphan Drug in August 2013. Eagle has been informed by the FDA that it will learn over the next four to six weeks if it has been granted the seven year Orphan Drug market exclusivity.
MARSHALL, Illinois - The Geoffrey Keller Memorial Open Water Swim held in honor of the late son of Curt and Kathleen Keller to raise funds to research better ways of managing Malignant Hyperthermia (MH) during surgery, to improve methods of detecting MH, and for MH awareness.
MedicAlert Foundation is pleased to announce that individuals living with Malignant Hyperthermia (MH) are now eligible to receive free medical IDs and live 24/7 emergency response services as the result of a grant obtained through the Sandi Ida Glickstein Fund at the Malignant Hyperthermia Association of the United States (MHAUS).
The Society of Ambulatory Anesthesia (SAMBA) has partnered with the Malignant Hyperthermia Association of the United States (MHAUS) to offer MHAUS membership benefits to active SAMBA members at a reduced rate.
The Geoffrey Keller Memorial Open Water Swim held in honor of the late son of Curt and Kathy Keller to raise funds to research better ways of managing Malignant Hyperthermia during surgery, to improve methods of detecting MH, and for MH awareness. Presented by Marshall, IL, the Geoff Keller Group of MHAUS, and Illinois Department of Natural Resources.
The American Association of Nurse Anesthetists (AANA) has partnered with the Malignant Hyperthermia Association of the United States (MHAUS) to offer MHAUS membership benefits at a reduced rate to Certified Registered Nurse Anesthetists who are active members of the AANA.
A substantial number of patients receive care in ambulatory surgical centers. Experts say storing the drug dantrolene at ambulatory surgical centers will save lives and is very cost effective.
If you are affected by Malignant Hyperthermia, Congenital Muscular Dystrophies or Congenital Myopathy Subtypes, the Malignant Hyperthermia Association of the United States and the Cure Congenital Muscle Disease organization are asking for your help to enable research and clinical trials by registering with the Congenital Muscle Disease International Registry (CMDIR).
March to be Malignant Hyperthermia Awareness and Training Month reminds us that a Malignant Hyperthermia crisis is best managed with preparation. Malignant Hyperthermia is often experienced in individuals undergoing, what was expected to be, routine surgery but can also happen to a person outside of the operating room. Malignant Hyperthermia is a genetic disorder found in an estimated 1 out of 2,000 people. Once triggered, the rapid progressive series of chain events include a body temperature of up to 107 degrees, muscle rigidity, system-wide organ failure, and possible death. Introduction of a treatment drug and advances in the understanding of MH have saved many lives since the syndrome was first described in the 1960s.
The Association of PeriOperative Registered Nurses (AORN) has partnered with the Malignant Hyperthermia Association of the United States (MHAUS) to offer MHAUS membership benefits to active AORN members for a reduced rate.
“MHAUS mourns the death of one of the pioneers in the study of Malignant Hyperthermia, Dr. Michael Denborough (July, 11, 1929 to February 8, 2014) of Australia, says MHAUS President Henry Rosenberg, M.D. Dr. Denborough and colleagues were the first to describe the disorder that was later named Malignant Hyperthermia. He did seminal work in describing the clinical and genetic basis for human MH. He also worked with pigs who developed “porcine stress syndrome” and showed how those animals could be a model for human MH.
Later in his life he worked hard as an advocate for anti-nuclear proliferation.
He was a great scientist, and a wonderful human being.”
Robert T. Dirksen, PhD, Department of Pharmacology and Physiology at University of Rochester Medical Center has been newly appointed to Chair the Professional Advisory Council (PAC) of the Malignant Hyperthermia Association of the United States (MHAUS).
Director of the Malignant Hyperthermia Investigation Unit at the Toronto General Hospital Sheila Riazi, MSc, MD, FRCPC has been newly appointed to the Professional Advisory Council (PAC) of the Malignant Hyperthermia Association of the United States (MHAUS).
Malignant Hyperthermia Experts from throughout Canada and the world will be attending the MH Scientific Conference in Toronto sponsored by the Malignant Hyperthermia Association of the United States in in conjunction with Toronto General Hospital Orlando on November 1 & 2, 2013.
There is mounting evidence that some people who are susceptible to Malignant hyperthermia (MH) will develop MH when exposed to hot environments or with exercise. This is could be problematic because without proper and prompt treatment, mortality associated with MH is extremely high; according to the Malignant Hyperthermia Association of the United States.
The 2013 Malignant Hyperthermia (MH) Scientific Conference is being held at the Chestnut Conference Centre, University of Toronto, Canada on November 1st and 2nd, 2013 and is sponsored by Malignant Hyperthermia Association of the United States (MHAUS) in conjunction with the University of Toronto. To register or for more information call: 011-1-607-674-7901, or email: [email protected].
The Malignant Hyperthermia Association of the United States (MHAUS) is very pleased to announce that Dr. Ron Litman, Professor of Anesthesiology and Critical Care at the Hospital of the University of Pennsylvania and the Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine has agreed to become the new Medical Director of the MH Hotline.
Learn the basics on how recognize, diagnose, and treat Malignant Hyperthermia by attending at the “MH Let’s Save a Life” conference where patients sit side-by-side with healthcare professionals, students, and families learning about MH from experts affiliated with MHAUS on September 14, 2013 from 10 am - 4 pm at St. Peter’s Health Partners - St. Peter’s Hospital located in Albany, NY. The inherited muscle disorder Malignant Hyperthermia (MH) is most often triggered by certain anesthetic drugs leading to a life-threatening crisis that requires prompt, specific treatment. In rare cases, MH may also be triggered by heat and exercise. The conference is sponsored by Malignant Hyperthermia Association of the United States in conjunction with St. Peter's Heath Partners: St. Peter’s Hospital, Albany Memorial, Samaritan Hospital and St. Mary's Hospital.
Learn the basics on how recognize, diagnose, and treat Malignant Hyperthermia by attending at the “MH Let’s Save a Life” conference where patients sit side-by-side with healthcare professionals, students, and families learning about MH from experts affiliated with MHAUS on September 14, 2013 from 10 am - 4 pm at St. Peter’s Health Partners - St. Peter’s Hospital located in Albany, NY. The inherited muscle disorder Malignant Hyperthermia (MH) is most often triggered by certain anesthetic drugs leading to a life-threatening crisis that requires prompt, specific treatment. In rare cases, MH may also be triggered by heat and exercise. The conference is sponsored by Malignant Hyperthermia Association of the United States in conjunction with St. Peter's Heath Partners: St. Peter’s Hospital, Albany Memorial, Samaritan Hospital and St. Mary's Hospital.